Aligos Licenses Pevifoscorvir Sodium to Amoytop for $445M China Deal
Event summary
- Aligos Therapeutics licenses pevifoscorvir sodium to Amoytop for Greater China, including Mainland China, Taiwan, Hong Kong, and Macau.
- Deal includes $25M upfront payment and up to $420M in milestones plus high single-digit royalties.
- Amoytop will fund development and commercialization in Greater China, where over 90 million people live with HBV.
- Aligos retains rights in the U.S., Europe, Japan, South Korea, and other markets.
- Transaction closing conditional on Amoytop shareholder approval, expected within 30 days.
The big picture
This deal positions Aligos to tap into Greater China's massive HBV market while maintaining global rights. Amoytop's established presence in hepatology and its approved PEGBING® therapy could accelerate pevifoscorvir sodium's development and commercialization. The $445M potential deal value underscores the strategic importance of this partnership in addressing chronic HBV, a condition affecting over 90 million people in the region.
What we're watching
- Regulatory Approval
- Whether Amoytop shareholders approve the transaction within the expected 30-day timeline.
- Clinical Success
- The pace at which pevifoscorvir sodium advances through Phase 2 trials and meets interim analysis milestones.
- Commercial Execution
- How Amoytop leverages its existing commercial infrastructure to drive adoption of pevifoscorvir sodium in Greater China.
Related topics